Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

CVD Still the Leading Cause of Death and Disease Globally

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

News Conference News ESC 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Michael O'Riordan

September 01, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

May 19, 2025

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

News Daily News

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

Michael O'Riordan

December 06, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

July 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

July 01, 2024

Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus

News Conference News HRS 2024

Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus

Michael O'Riordan

May 23, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

News Conference News HFSA 2023

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

October 13, 2023

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

Women Less Likely Than Men to Experience SCD During Sports

News Daily News

Women Less Likely Than Men to Experience SCD During Sports

Michael O'Riordan

December 21, 2021

Cancer Survivors With Heart Failure Respond Well to CRT

News Conference News HRS 2019

Cancer Survivors With Heart Failure Respond Well to CRT

May 14, 2019

Best-Yet Study of Footballers Raises New Questions Over Preparticipation Cardiac Tests for Athletes

News Daily News

Best-Yet Study of Footballers Raises New Questions Over Preparticipation Cardiac Tests for Athletes

Michael O'Riordan

August 09, 2018

Genetic Testing for Cardiomyopathy Less Useful for Racial Minorities

News Daily News

Genetic Testing for Cardiomyopathy Less Useful for Racial Minorities

March 06, 2018

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

News Conference News AHA 2017

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

November 14, 2017

News Daily News

Alcohol Septal Ablation Rivals Myectomy for Obstructive Hypertrophic Cardiomyopathy

October 23, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.